Abstract
Interest in Central Nervous System (CNS) inflammation has rapidly grown over the past decade driven by the increasing evidence indicating that chronic inflammation and neuroinflammation in the brain may play an important role in the progressive neuronal cell death in many chronic CNS diseases, such as Alzheimer and Parkinson’s diseases, traumatic brain injury, spinal cord injury (SCI), as well as pathologies associated with CNS infections. In peripheral tissues, generally inflammation has a protective role limiting the survival and proliferation of invading pathogens, promoting tissue repair and recovery. This innate response normally resolves over a few weeks, accompanyied by tissue repair aided by macrophages recruited to the site. However, when the inflammatory response does not undergo resolution, it might turn into chronic inflammation. Any chronic inflammatory process can damage healthy tissue and the brain may be particularly vulnerable, since destroyed neurons can not be replaced. Recently, several reports have suggested that phosphodiesterases (PDEs) are new targets for central nervous system (CNS) diseases. All the PDEs are expressed in the CNS, making this gene family a particularly attractive source of new targets for the treatment of psychiatric and neurodegenerative disorders. Significantly, all neurons express multiple PDEs, which differ in cyclic nucleotide specificity, affinity, regulatory control and subcellular compartmentalization. Therefore, PDEs inhibition represents a mechanism through which it could be possible to precisely modulate neuronal activity. In this article, we review the current state of art of PDEs in the CNS diseases associated with neuroinflammation.
Keywords: Alzheimer’s disease, chronic Inflammation, neuroinflammation, Parkinson’s disease, PDE inhibitors, spinal cord injury.
Current Medicinal Chemistry
Title:Phosphodiesterase as a New Therapeutic Target for the Treatment of Spinal Cord Injury and Neurodegenerative Diseases
Volume: 21 Issue: 24
Author(s): Irene Paterniti, Emanuela Esposito and Salvatore Cuzzocrea
Affiliation:
Keywords: Alzheimer’s disease, chronic Inflammation, neuroinflammation, Parkinson’s disease, PDE inhibitors, spinal cord injury.
Abstract: Interest in Central Nervous System (CNS) inflammation has rapidly grown over the past decade driven by the increasing evidence indicating that chronic inflammation and neuroinflammation in the brain may play an important role in the progressive neuronal cell death in many chronic CNS diseases, such as Alzheimer and Parkinson’s diseases, traumatic brain injury, spinal cord injury (SCI), as well as pathologies associated with CNS infections. In peripheral tissues, generally inflammation has a protective role limiting the survival and proliferation of invading pathogens, promoting tissue repair and recovery. This innate response normally resolves over a few weeks, accompanyied by tissue repair aided by macrophages recruited to the site. However, when the inflammatory response does not undergo resolution, it might turn into chronic inflammation. Any chronic inflammatory process can damage healthy tissue and the brain may be particularly vulnerable, since destroyed neurons can not be replaced. Recently, several reports have suggested that phosphodiesterases (PDEs) are new targets for central nervous system (CNS) diseases. All the PDEs are expressed in the CNS, making this gene family a particularly attractive source of new targets for the treatment of psychiatric and neurodegenerative disorders. Significantly, all neurons express multiple PDEs, which differ in cyclic nucleotide specificity, affinity, regulatory control and subcellular compartmentalization. Therefore, PDEs inhibition represents a mechanism through which it could be possible to precisely modulate neuronal activity. In this article, we review the current state of art of PDEs in the CNS diseases associated with neuroinflammation.
Export Options
About this article
Cite this article as:
Paterniti Irene, Esposito Emanuela and Cuzzocrea Salvatore, Phosphodiesterase as a New Therapeutic Target for the Treatment of Spinal Cord Injury and Neurodegenerative Diseases, Current Medicinal Chemistry 2014; 21 (24) . https://dx.doi.org/10.2174/0929867321666140217102428
DOI https://dx.doi.org/10.2174/0929867321666140217102428 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Beta-Adrenoreceptor Modulation of Metabolic, Endocrine and Immunologic Function During Critical Illness
Endocrine, Metabolic & Immune Disorders - Drug Targets Neuroprotective Actions of Flavones and Flavonols: Mechanisms and Relationship to Flavonoid Structural Features
Central Nervous System Agents in Medicinal Chemistry A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery The Plastic Phenomenon Underlying the Associative Processes in the Addictive Properties of Diazepam and Other Psychoactive Drugs
Mini-Reviews in Medicinal Chemistry Melatonin, Autophagy and Intestinal Bowel Disease
Current Pharmaceutical Design Patents on Non-Viral Mediated Gene Delivery
Recent Patents on DNA & Gene Sequences Targeting Cyclooxygenase and Nitric Oxide Pathway Cross-Talk: A New Signal Transduction Pathway for Developing More Effective Anti- Inflammatory Drugs
Current Signal Transduction Therapy HCN Pacemaker Channels and Pain: A Drug Discovery Perspective
Current Pharmaceutical Design Use Of External Intrathecal Infusion Pumps In The Management Of Septic Complications: A Case Report
Endocrine, Metabolic & Immune Disorders - Drug Targets Sulfonamide Agents for Treatment of Staphylococcus MRSA and MSSA Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders
Current Drug Metabolism Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation
CNS & Neurological Disorders - Drug Targets Stem Cells: An Overview of the Current Status of Therapies for Central and Peripheral Nervous System Diseases
Current Medicinal Chemistry Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Sub-Chronic Exposure of Non-Observable Adverse Effect Dose of Terbufos Sulfone: Neuroinflammation in Diabetic and Non-Diabetic Rats
CNS & Neurological Disorders - Drug Targets Lung Volume Reduction in Patients with COPD: Physiological and Clinical Implications
Current Respiratory Medicine Reviews Synaptic Activity-Regulated Wnt Signaling in Synaptic Plasticity, Glial Function and Chronic Pain
CNS & Neurological Disorders - Drug Targets Modifying Radiation Damage
Current Drug Targets Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis
Current Stem Cell Research & Therapy Botulinum Toxin as a Neuro-Relearning Drug Tool in Motor Paralytic Disorders
Current Drug Therapy